Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Multicenter, Parallel-Arm Phase 3 Study to Compare the Efficacy, Pharmacodynamics, Safety, and Immunogenicity Between Bmab 1000 and Prolia® in Postmenopausal Women With Osteoporosis

NCT05345691 is registered in ClinicalTrials.gov with Biocon Biologics UK Ltd as lead sponsor.

NCT NCT05345691
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05345691 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Multicenter, Parallel-Arm Phase 3 Study to Compare the Efficacy, Pharmacodynamics, Safety, and Immunogenicity Between Bmab 1000 and Prolia® in Postmenopausal Women With Osteoporosis
Lead sponsor
Biocon Biologics UK Ltd
Phase
Phase 3
Overall status
Completed
Start date
May 24, 2022
Completion date
June 12, 2024
Enrollment
479 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

postmenopausal women with osteoporosis